Efficacy and safety of dulaglutide in the treatment of type 2 diabetes
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes mellitus patients
- Registration Number
- JPRN-UMIN000027255
- Lead Sponsor
- Department of nephrology, Matsunami general hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with gastrointestinal bleeding, malignant tumor, liver cirrhosis, and thyroid function abnormalities.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body composition (body fat percentage, fat mass, muscle mass, etc.) in the body composition analyzer (MLT - 50) on 3 months and 6 months after the administration of dulaglutide.
- Secondary Outcome Measures
Name Time Method Changes of HbA1c, GA, body weight before and after the administration of dulaglutide.